Literature DB >> 7585536

Antiproliferative and angiostatic activity of suramin analogues.

A Firsching1, P Nickel, P Mora, B Allolio.   

Abstract

Suramin, a polyanionic naphthylurea, represents a novel class of antineoplastic drugs with a variety of activities against tumor cell proliferation. However, its clinical use is hampered by serious toxicity. To gain more insight into structure-activity relationships of suramin, we investigated the antiproliferative action of suramin and 19 suramin analogues in vitro using 5 different human cell lines (HT29, MCF7, SW13, PC3, and T47D). In addition, for seven analogues the angiostatic potential with and without hydrocortisone was assessed using a modified chorioallantois membrane assay. Only the symmetric compounds exhibited antiproliferative action in vitro; several analogues were more active than suramin (e.g., NF031, NF037, NF326). Suramin analogues with six sulfonic acid groups showed a wide range of activity in HT29 cells (IC50 = 43-390 microM), indicating that besides the polyanionic feature, other structural elements are important (e.g., stiffness of the bridge between the two terminal naphthyl rings). Some of the smaller ureas with only four sulfonic acid groups retained significant antiproliferative activity. Compounds active in cell lines also inhibited angiogenesis in the chorioallantois membrane assay, suggesting a similar mode of action. Hydrocortisone increased the angiostatic effect of most but not all of the screened suramin analogues. These findings may guide the use of suramin analogues for improved antitumor therapy in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585536

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Suramin affects coupling of rhodopsin to transducin.

Authors:  Nicole Lehmann; Gopala Krishna Aradhyam; Karim Fahmy
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

Review 2.  Platelet-derived growth factor in human brain tumors.

Authors:  M Kirsch; J C Wilson; P Black
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

3.  NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.

Authors:  Pavel Krejci; Shunichi Murakami; Jirina Prochazkova; Lukas Trantirek; Katarina Chlebova; Zhufeng Ouyang; Anie Aklian; Jiri Smutny; Vitezslav Bryja; Alois Kozubik; William R Wilcox
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

Review 4.  Anti-angiogenic treatment strategies for malignant brain tumors.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

5.  Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status.

Authors:  H J Bernsen; P F Rijken; J P Peters; J H Bakker; R H Boerman; P Wesseling; A J van der Kogel
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

6.  Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.

Authors:  Y Kakeji; B A Teicher
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 7.  An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.

Authors:  W J Gradishar
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

8.  Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3.

Authors:  T Kimura; T Watanabe; K Sato; J Kon; H Tomura; K Tamama; A Kuwabara; T Kanda; I Kobayashi; H Ohta; M Ui; F Okajima
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

9.  The anti-angiogenic potential of (±) gossypol in comparison to suramin.

Authors:  Gönül Ulus; A Tansu Koparal; Kemal Baysal; Günay Yetik Anacak; N Ülkü Karabay Yavaşoğlu
Journal:  Cytotechnology       Date:  2018-08-19       Impact factor: 2.058

10.  Heparin-mimetic sulfated peptides with modulated affinities for heparin-binding peptides and growth factors.

Authors:  Sung Hye Kim; Kristi L Kiick
Journal:  Peptides       Date:  2007-08-19       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.